secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110789
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027
----------------------------------------------------------------------------

- Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.
- Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.
- Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.
- G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.
- No revenue reported; clinical-stage immunology company with no approved products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/0001104659-25-110789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/tm2531128d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer